Compare Novartis AG (NVS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Smith & Nephew plc — how do they compare? Novartis AG trades at $152.33 (market cap $295.37B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Novartis AG is far larger — about 23.6× Smith & Nephew plc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | SNN | |
|---|---|---|
Market Cap | $295.37B | $12.54B |
Sector | Health | Health |
52-Week High | $168.62 | $38.70 |
52-Week Low | $119.31 | $28.73 |
Enterprise Value | $336.69B | $15.57B |
Dividend Yield | 3.07% | 2.65% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
